Clinical Trial Update: Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing SECOX to Sorafenib as first-line therapy in advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• SECOX
• Sorafenib (Sorafenib)

Snippet

Sponsor: The University of Hong Kong | Conditions: Carcinoma, Hepatocellular, Secondary | Phase 2 | Status: COMPLETED